SCHEDULE: Aberdeen Group Discloses uniQure Stake

Aberdeen Group plc and abrdn Inc. have reported a combined beneficial ownership of 4.52% in uniQure N.V. ordinary shares as of June 30, 2026.

Summary

• Aberdeen Group plc and its subsidiary abrdn Inc. have filed a Schedule 13G, indicating their beneficial ownership of uniQure N.V. ordinary shares.
• The total number of shares beneficially owned by both entities is 2,848,117.
• This holding represents 4.52% of the class of securities.
• Both entities share the power to vote and dispose of these shares.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of institutional ownership and does not provide new operational or financial information about the company itself.

Positives

• Aberdeen Group and abrdn Inc. collectively hold a significant stake of 4.52% in uniQure N.V., indicating institutional investor confidence.
• The filing confirms that the shares are held in the ordinary course of business, suggesting a standard investment approach rather than a hostile takeover attempt.

Negatives

• The filing does not contain any negative financial results or operational challenges for uniQure N.V.

Risks

• While not explicitly stated as risks in this filing, significant institutional ownership can sometimes lead to increased shareholder activism or pressure on management for strategic changes.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from uniQure N.V.

Management Comments

• "Aberdeen Group plc is the parent company."
• "abrdn Holdings Limited is the intermediate holding company for abrdn Inc."
• "abrdn Inc. beneficially owns on behalf of our underlying clients less than 5% of the outstanding shares of the security class being reported on this Schedule 13G."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors crossing certain ownership thresholds. Aberdeen's filing indicates continued institutional interest in the gene therapy sector, where uniQure operates.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can be viewed positively as a sign of confidence, but does not directly impact current share value without further context.

Next Steps

• Continued monitoring of Aberdeen Group's ownership stake in uniQure N.V.

Key Dates

Keywords

uniQure N.V., Schedule 13G, Aberdeen Group plc, abrdn Inc., beneficial ownership, ordinary shares, institutional investor, SEC filing